EOLS
Evolus, Inc.Company Information
- Company Name
- Evolus, Inc.
- CIK
- CIK0001570562
- Category
- Accelerated filer
- Ticker: Exchange
- EOLS: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- EOLS
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-08-15
- Last sale
- 2026-09-02
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 281,412
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 48,509,970
- Shares outstanding
- 65,929,112
- Ownership
- 73.58%
Earnings Market Reaction
- Filing date
- 2026-08-05
- Price on filing date
- —
- 1-month reaction
- 43.69%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 45 | 50 | 54 | 44 | 62 | 68 | 87 | 85 | 94 | 97 | 63 | 39 | ||||||
| Accounts Receivable Net Current | 62 | 52 | 55 | 50 | 48 | 47 | 48 | 45 | 43 | 34 | 31 | 30 | ||||||
| Inventory Net | 41 | 25 | 27 | 33 | 26 | 10 | 12 | 15 | 13 | 12 | 11 | 18 | ||||||
| Prepaid Expense Current | 4 | 5 | 4 | 5 | 5 | 3 | 3 | 3 | 6 | 6 | 6 | 4 | ||||||
| Other Assets Current | 15 | 8 | 4 | 3 | 4 | 3 | 1 | 2 | 2 | 2 | 2 | 2 | ||||||
| Assets Current | 168 | 139 | 143 | 135 | 145 | 132 | 151 | 150 | 158 | 150 | 112 | 92 | ||||||
| Property Plant And Equipment Net | 5 | 5 | 5 | 5 | 4 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | ||||||
| Operating Lease Right Of Use Asset | 6 | 7 | 7 | 7 | 1 | 7 | 7 | 1 | 5 | 6 | 6 | 6 | ||||||
| Intangible Assets Net Excluding Goodwill | 46 | 47 | 48 | 49 | 49 | 49 | 49 | 47 | 46 | 47 | 47 | 47 | ||||||
| Goodwill | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | ||||||
| Other Assets Noncurrent | 2 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | ||||||
| Assets | 248 | 221 | 226 | 219 | 229 | 213 | 233 | 230 | 234 | 226 | 189 | 168 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 44 | 20 | 23 | 23 | 23 | 16 | 9 | 14 | 10 | 11 | 4 | 12 | ||||||
| Accrued Liabilities Current | 38 | 32 | 36 | 30 | 28 | 27 | 41 | 35 | 33 | 25 | 34 | 27 | ||||||
| Operating Lease Liability Current | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | ||||||
| Litigation Reserve Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Liabilities Current | 99 | 68 | 75 | 67 | 64 | 56 | 63 | 61 | 54 | 47 | 48 | 49 | ||||||
| Operating Lease Liability Noncurrent | 5 | 6 | 6 | 7 | 7 | 6 | 7 | 7 | 5 | 5 | 5 | 5 | ||||||
| Contractual Obligation | - | - | - | - | - | 33 | 34 | 35 | 35 | 35 | 36 | 39 | ||||||
| Secured Long Term Debt | - | - | 146 | 146 | 145 | 122 | 122 | 121 | 121 | 121 | 120 | 95 | ||||||
| Long Term Debt Noncurrent | 157 | 156 | - | - | - | - | - | - | - | - | - | - | ||||||
| Deferred Income Tax Liabilities Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 279 | 249 | 249 | 248 | 247 | 220 | 227 | 224 | 214 | 208 | 210 | 187 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 649 | 643 | 638 | 633 | 627 | 623 | 616 | 609 | 603 | 591 | 539 | 528 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -0 | -0 | -0 | -1 | -1 | -1 | -1 | -1 | -1 | -0 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -680 | -672 | -661 | -661 | -645 | -628 | -609 | -603 | -583 | -572 | -559 | -547 | ||||||
| Stockholders Equity | -31 | -29 | -23 | -29 | -19 | -7 | 6 | 6 | 19 | 18 | -21 | -19 | ||||||
| Liabilities And Stockholders Equity | 248 | 221 | 226 | 219 | 229 | 213 | 233 | 230 | 234 | 226 | 189 | 168 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | ||||||
| Common Stock Shares Issued | 66 | 66 | 65 | 65 | 65 | 64 | 63 | 63 | 63 | 62 | 58 | 57 | ||||||
| Shares Outstanding | 66 | 66 | 65 | 65 | 65 | 64 | 63 | 63 | 63 | 62 | 58 | 57 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialEvolus, Inc. (EOLS) — SEC Financial Statements & Analysis
Evolus, Inc. (EOLS) is a pharmaceutical preparations company, incorporated in DE. Evolus, Inc. trades on Nasdaq as: EOLS. Evolus, Inc. (EOLS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, Evolus, Inc. carries a market cap of $457.55M, a P/E ratio of -13.33x, a P/B ratio of -14.81x, a P/S ratio of 1.45x, an enterprise value of $569.12M, and an EV/EBITDA multiple of -58.17x. On profitability, it posts a gross margin of 66.74%, an operating margin of -5.90%, a net margin of -10.85%, a Return on Equity (ROE) of 138.57%, a Return on Assets (ROA) of -14.40%, and a Return on Invested Capital (ROIC) of -23.69%. Per share, it reports EPS of $-0.52, diluted EPS of $-0.52, free cash flow per share of $-0.28, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 13.87% year-over-year, net income growth of -44.62% year-over-year, and EPS growth of -45.79% year-over-year. On the balance sheet, it maintains a current ratio of 1.70x, a quick ratio of 1.24x, working capital of $68.81M, a debt-to-equity ratio of -9.03x, a debt ratio of 1.12, an interest coverage ratio of -1.15x, free cash flow of $-18.28M (TTM), and net debt of $111.57M. Figures sourced from SEC EDGAR.
- Market Cap
- $457.55M
- P/E TTM
- -13.33x
- EPS TTM
- $-0.52
- P/B TTM
- -14.81x
- ROE TTM
- 138.57%
- ROA TTM
- -14.40%
- Debt To Equity
- -9.03x
- Free Cash Flow TTM
- $-18.28M
- Net Revenue TTM Growth 1Y
- 13.87%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Evolus, Inc. in?
Evolus, Inc. (EOLS) operates in the Pharmaceutical Preparations industry.
What exchange does EOLS trade on?
Evolus, Inc. (EOLS) trades on the Nasdaq.
Where is Evolus, Inc. incorporated?
Evolus, Inc. is incorporated in DE.
When was Evolus, Inc. (EOLS)'s most recent SEC filing?
Evolus, Inc. (EOLS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05.
What is EOLS's market cap?
Evolus, Inc. (EOLS) has a market capitalization of $457.55M as of 2026-06-30.
What is EOLS's EPS (earnings per share)?
Evolus, Inc. (EOLS)'s trailing twelve month EPS is $-0.52 as of 2026-06-30.
What is EOLS's ROE (return on equity)?
Evolus, Inc. (EOLS)'s trailing twelve month Return on Equity (ROE) is 138.57% as of 2026-06-30.
What is EOLS's ROA (return on assets)?
Evolus, Inc. (EOLS)'s trailing twelve month Return on Assets (ROA) is -14.40% as of 2026-06-30.
What is EOLS's ROIC (return on invested capital)?
Evolus, Inc. (EOLS)'s trailing twelve month Return on Invested Capital (ROIC) is -23.69% as of 2026-06-30.
What is EOLS's EV/EBITDA?
Evolus, Inc. (EOLS)'s trailing twelve month EV/EBITDA is -58.17x as of 2026-06-30.